Amyotrophic Lateral Sclerosis Treatment Market Affects 30,000 People in the United States, With 5,000 New Cases Diagnosed Each Year
Amyotrophic lateral sclerosis is a progressive
neurodegenerative disorder. It affects the nerve cells in the central nervous
system that controls the voluntary muscles. Muscle twitching, weakness, and
stiff muscles are some of the symptoms of the amyotrophic lateral sclerosis.
Amyotrophic lateral sclerosis is also known as Lou Gehrig's disease.
The rising prevalence of amyotrophic
lateral sclerosis is a prime factor driving growth of the amyotrophic lateral
sclerosis treatment market. According to The Johns Hopkins University, it
affects as many as 30,000 in the United States, with 5,000 new cases diagnosed
each year. Estimates suggest that ALS is responsible for as many as five of
every 100,000 deaths in people aged 20 or older. The growing geriatric
population is increasing the prevalence of amyotrophic lateral sclerosis which
is again propelling the growth of the amyotrophic
lateral sclerosis treatment market.
According to the United Nation, in 2019, there were 703 million persons aged 65
years or over in the global population. This number is projected to double to
1.5 billion in 2050.
North America is expected to gain significant growth over
the forecast period and this is attributed to increasing healthcare expenditure
coupled with the high prevalence of this disorder in the region. According to
the Centers for Medicare & Medicaid Services, the U.S. health care spending
grew 4.6 percent in 2018, reaching $3.6 trillion or $11,172 per person. As a
share of the nation's Gross Domestic Product, health spending accounted for
17.7 percent.
Key Developments:
1. In February 2020, NeuroSense Therapeutics, a Biotech company
developing PrimeC, a combination drug that aims to slow or halt ALS
progression, announced the initiation of two clinical studies to evaluate the
benefit of PrimeC for ALS patients.
2. In July 2020, Clinigen Group plc. the global pharmaceutical
and services company, announces that the US Food and Drug Administration (FDA)
Office of Orphan Products Development (OOPD) has granted Orphan Drug
Designation for aldesleukin in the treatment of Amyotrophic Lateral Sclerosis
(ALS).
3. In November 2019, Exservan™ (riluzole) Oral Film has
received early-action approval from the US Food and Drug Administration (FDA)
for the treatment of amyotrophic lateral sclerosis (ALS), an orphan disease.
4. In January 2020, Alexion Pharmaceuticals, Inc. announced the
planned initiation of a pivotal Phase 3 study of ULTOMIRIS® (ravulizumab) in
amyotrophic lateral sclerosis (ALS).
5. In October 2020, Zhittya Genesis Medicine announces that it
has been approved to initiate clinical trials in Mexico for the treatment of Amyotrophic
Lateral Sclerosis (ALS)
Comments
Post a Comment